FDA Human Factors: De-Risking AI SaMD for Cardiac Investors

The promise of AI in healthcare is immense, yet its clinical integration hinges on more than just algorithmic prowess. For AI-driven Software as a Medical Device (SaMD), the interface through which clinicians interact with these powerful tools can be a critical point of failure. Use errors in medical software can be fatal, making human factors engineering not merely a best practice, but a core regulatory requirement.

The FDA’s Uncompromising Stance on Human Factors in SaMD

The Food and Drug Administration (FDA) has consistently emphasized human factors (HF) and usability engineering (UE) as foundational pillars for medical device safety, a stance that extends unequivocally to AI-driven SaMD. The agency’s commitment to preventing use-related hazards is codified in its “Guidance on Applying Human Factors and Usability Engineering to Medical Devices” FDA human factors guidance document. An updated final version of this guidance was released on August 3, 2026, marking the first revision since 2016, which modernizes terminology and aligns with current regulatory frameworks. This complete document outlines the FDA’s expectations for manufacturers, making it clear that a strong human factors validation process is non-negotiable for securing market authorization. The FDA’s focus is on ensuring that devices are designed to minimize the potential for user error, even when used by individuals with varying levels of experience or under stressful clinical conditions. This is particularly salient for AI health tools, where complex outputs or subtle interface cues could be misinterpreted, leading to adverse patient outcomes. The guidance mandates a systematic approach, starting from early-stage user research and iterative design, culminating in rigorous summative usability testing. The goal is to identify and mitigate potential use errors before a device reaches the market, thereby preventing postmarket adverse events that can lead to recalls and patient harm.

Deconstructing Summative Usability Testing for SaMD

At the heart of FDA-compliant human factors validation for SaMD lies summative usability testing. This is not merely a check-the-box exercise, but a critical evaluation designed to expose use errors under simulated real-world conditions. The FDA references the Association for the Advancement of Medical Instrumentation (AAMI) standards, particularly ANSI/AAMI HE75:2025, as authoritative guidance for conducting these tests ANSI/AAMI HE75 standards overview. This standard was significantly updated as of November 18, 2025, and is now considered the primary human factors reference. Key steps in an FDA-compliant human factors validation test include:

• Defining Critical Tasks: Identifying the most important user tasks whose incorrect performance or non-performance could lead to serious harm. For an AI SaMD, this might include tasks related to data input, interpretation of AI-generated insights, or overriding AI recommendations.
• Recruiting Representative Users: Engaging actual end-users who possess the relevant clinical background, experience, and training. This ensures that the testing environment accurately reflects the intended user population.
• Simulating Realistic Use Environments: Conducting testing in conditions that closely mimic the intended clinical setting, including distractions, noise levels, and workflow interruptions. This is vital for AI SaMD, which may be integrated into fast-paced clinical workflows.
• Observing and Documenting Use Errors: Carefully recording all observed use errors, close calls, and user difficulties. This includes both overt errors and subtle hesitations or misunderstandings that could escalate into errors.
• Analyzing Root Causes: For every identified use error, performing a thorough root cause analysis to determine whether the error stems from the device interface, user training, or environmental factors.
• Implementing Design Changes and Re-testing: Based on the analysis, making necessary design modifications to the SaMD interface and, if critical errors persist, conducting further summative testing to confirm the effectiveness of the changes.

The FDA expects complete documentation of this entire process, including the test plan, raw data, analysis, and conclusions. This documentation forms an important part of the premarket submission for SaMD clearance.

The Peril of Neglecting Usability: Lessons from MAUDE

The consequences of inadequate human factors engineering are starkly evident in the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database. This public repository of adverse event reports frequently highlights usability-related issues as common causes of medical device recalls and patient harm FDA MAUDE database search. While specific data on AI SaMD-related recalls due to usability are still emerging given the technology’s relative novelty, historical trends from traditional medical devices offer a cautionary tale. Common usability-related recall causes found in MAUDE reports often include:

• Confusing or ambiguous user interface controls.
• Lack of clear feedback mechanisms, leading users to believe an action was performed when it was not.
• Difficult-to-read displays or alarms.
• Inadequate or poorly designed alarm systems, leading to alarm fatigue or missed critical alerts.
• Complex workflows that are prone to steps being skipped or performed out of sequence.
• Inconsistent interaction patterns across different functions of a device.

For AI SaMD, these issues can be compounded by the inherent complexity of AI outputs, the potential for algorithmic opacity, and the need for clinicians to trust and appropriately act upon AI-generated insights. A SaMD that provides an accurate diagnosis but presents it in a way that is easily misunderstood or overlooked poses as much, if not more, risk than an inaccurate one.

Rigorous Usability Documentation: The Gateway to SaMD Clearance

For usability engineers, clinical safety officers, and regulatory auditors, the message is clear: rigorous usability documentation is non-negotiable for securing SaMD clearance. The FDA views human factors engineering as an integral part of risk management, ensuring that the benefits of an AI health tool outweigh its risks, including those related to user interaction. Companies that fail to integrate human factors engineering throughout their SaMD development lifecycle face significant regulatory hurdles. A deficiency in usability documentation can lead to delays in clearance, requests for additional testing, or even outright refusal of market authorization. Plus, postmarket surveillance can uncover usability issues, leading to costly recalls, reputational damage, and potential enforcement actions. As the regulatory field for AI in healthcare continues to evolve, the foundational principles of human factors engineering remain constant. By proactively addressing potential use errors through strong design and validation, manufacturers of AI SaMD can not only simplify their regulatory pathway but, more importantly, contribute to safer and more effective patient care. This approach, grounded in official FDA usability guidance and AAMI standards, is the bedrock upon which trustworthy and impactful AI health tools are built.